Sun Pharma Advanced Research Company (SPARC) Q2 24/25 earnings summary

Executive summary

• Reported a net loss of ₹10,733 lakhs for Q2 FY25, widening from ₹8,642 lakhs in Q2 FY24 and ₹9,590 lakhs in Q1 FY25.

• Revenue from operations declined to ₹1,286 lakhs in Q2 FY25 from ₹2,118 lakhs in Q2 FY24 and ₹1,681 lakhs in Q1 FY25.

• The business continues as a going concern, supported by unutilized credit limits and a promoter support letter.

Financial highlights

• Total income for H1 FY25 was ₹2,947 lakhs, down from ₹4,513 lakhs in H1 FY24.

• Total expenses for H1 FY25 were ₹23,394 lakhs, compared to ₹24,558 lakhs in H1 FY24.

• Basic and diluted loss per share for H1 FY25 was ₹6.25, compared to ₹5.60 in H1 FY24.

Outlook and guidance

• The company maintains its going concern status despite recurring losses, relying on available credit and promoter support.